Chronic hepatitis B liver fibrosis
Conditions
Interventions
Treatment group (syndrome of Qi-deficiency and collateral-obstruction of hepatitis B liver fibrosis):Entecavir tablets (Trade name: Reifen Suzhou Dongrui Pharmaceutical Co. LTD.) 1 tablet (0.5mg) once
Control group (Hepatitis B liver fibrosis syndrome of qi deficiency and collaterals obstruction):Entecavir tablet (Trade name: Reifen Suzhou Dongrui Pharmaceutical Co. LTD.) 1 tablet (0.5mg) once a da
Sponsors
Chengdu Public Health Clinical Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria of liver fibrosis 2) those aged between 18 and 75 years; 3)The person who signed the informed consent; 4) After strict syndrome differentiation patients whose clinical symptoms were consistent with Qi-deficiency and collateral-obstruction syndrome were included in the liver fibrosis Qi-deficiency and collateral-obstruction syndrome group; 5) After strict syndrome differentiation patients whose clinical symptoms did not conform to Qi-deficiency and collateral-obstruction syndrome were included in the non-Qi-deficiency and collateral-obstruction syndrome group of liver fibrosis.
Exclusion criteria
Exclusion criteria: 1) those who do not meet the inclusion criteria; 2) poor compliance; 3) Those who are participating in other scientific research projects; 4) Liver fibrosis with serious complications; 5) Patients with severe heart brain lung and kidney diseases or tumors; 6) Pregnant or lactating women; 7) Suffering from mental illness or being unable to work together.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum liver fibrosis indicators;Spatiotemporal index of liver tissue;Information on TCM symptoms;Total transcriptomic indicators of peripheral blood;Liver function;Objectify tongue pulse and eye information;Hepatitis B two in half quantitative;transient elastography;Serum proteomic indicators;ultrasonic;Hepatitis B virus DNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| alpha-fetoprotein;Blood clotting time;CT; | — |
Countries
China
Contacts
Public ContactWang Yuelian
Chengdu Public Health Clinical Medical Center
Outcome results
None listed